Diplomat Pharmacy, Inc. (NYSE:DPLO) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday. The firm currently has a $24.00 price objective on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 13.69% from the stock’s current price.

According to Zacks, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan. “

A number of other research firms also recently weighed in on DPLO. BidaskClub raised Diplomat Pharmacy from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 5th. Needham & Company LLC reissued a “buy” rating and issued a $23.75 price target (up previously from $19.75) on shares of Diplomat Pharmacy in a research note on Wednesday, October 4th. Robert W. Baird raised Diplomat Pharmacy to a “positive” rating and increased their price target for the company from $20.00 to $24.00 in a research note on Monday, September 18th. Finally, TheStreet raised Diplomat Pharmacy from a “d+” rating to a “c-” rating in a research note on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, three have given a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $19.69.

Diplomat Pharmacy (NYSE DPLO) traded up 2.13% during mid-day trading on Tuesday, hitting $21.11. The stock had a trading volume of 552,697 shares. Diplomat Pharmacy has a 1-year low of $12.25 and a 1-year high of $29.36. The firm has a market cap of $1.44 billion, a P/E ratio of 115.36 and a beta of 0.73. The stock has a 50 day moving average of $19.08 and a 200-day moving average of $16.94.

Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Monday, August 7th. The company reported $0.25 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.10. The company had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.14 billion. Diplomat Pharmacy had a return on equity of 7.97% and a net margin of 0.27%. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.23 EPS. Analysts predict that Diplomat Pharmacy will post $0.75 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Diplomat Pharmacy, Inc. (DPLO) Upgraded to Strong-Buy at Zacks Investment Research” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/10/diplomat-pharmacy-inc-dplo-upgraded-to-strong-buy-at-zacks-investment-research.html.

A number of hedge funds have recently added to or reduced their stakes in the business. Eqis Capital Management Inc. increased its holdings in Diplomat Pharmacy by 13.3% during the 3rd quarter. Eqis Capital Management Inc. now owns 21,238 shares of the company’s stock worth $440,000 after purchasing an additional 2,490 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Diplomat Pharmacy during the 2nd quarter worth about $610,000. Koch Industries Inc. bought a new position in Diplomat Pharmacy during the 2nd quarter worth about $308,000. Verition Fund Management LLC bought a new position in Diplomat Pharmacy during the 2nd quarter worth about $341,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Diplomat Pharmacy by 3.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 37,644 shares of the company’s stock worth $557,000 after purchasing an additional 1,211 shares in the last quarter. Hedge funds and other institutional investors own 69.90% of the company’s stock.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.